All News
EULAR 2022 Featured Industry Abstracts
Below is a collection of several EULAR 2022 abstracts highlighted in recent press releases from companies sponsoring major clinical trials. You can search the EULAR site for these abstract and others here.
Read Article
Giant Cell Arteritis Growing More Lethal
d
MedPage Today
Mortality rates among patients with giant cell arteritis (GCA) in Canada's Ontario province rose by 15% from 2000 to 2018, a new study found, even as the general population saw declines in overall mortality.
Read Article
#EULAR2022 AAV Reccs for Steroids: start prednisone 50-75 mg/d prednisone and taper to goal 5 mg/day by 4-5 months based on #PEXIVAS @rheumnow https://t.co/6gIfme4HXH
TheDaoIndex KDAO2011 ( View Tweet)
Overarching principles of #EULAR2022 Ax Spa Updated Reccs @Rheumnow https://t.co/g6Hd9NE1vB
TheDaoIndex KDAO2011 ( View Tweet)
#EULAR2022 updated ASAS-EULAR guidelines for the management of axSpA review with Dr. @sofiaramiro82 @RheumNow https://t.co/SHg4y49auA
Dr. Rachel Tate uptoTate ( View Tweet)
#EULAR2022 ASAS Updated Reccs: Treatment Algorithm @rheumnow https://t.co/YEdhrAX0lT
TheDaoIndex KDAO2011 ( View Tweet)
#EULAR2022 ASAS-EULAR guidelines for axSpA with Dr. @sofiaramiro82. Below are the recommendations including b/tsDMARDs. If ASDAS > 2.1 the recommendations call for consideration for TNFi, IL17i, or JAKi. Re-evaluate after at least 12 weeks on tx and for co-morbidities. @RheumNow https://t.co/mryL3YmtzN
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. @sofiaramiro82 important conclusion considerations from the ASAS-EULAR guidelines for axSpa. @RheumNow #EULAR2022 https://t.co/7Q3zxo7euj
Dr. Rachel Tate uptoTate ( View Tweet)
Nice session (joint chaired @AurelieRheumo) on AI in rheumatology - particularly from Michael Barnes on deciphering the polyome.
It's a whole door opened with insights beyond, but some careful steps necessary first (& cross-disciplinary footsteps to follow)
#EULAR2022 @RheumNow https://t.co/vLfDvcEnxo
David Liew drdavidliew ( View Tweet)
#EULAR2022 RA Recommendations
⭐️Last update 2019
▶️GC use when starting csDMARD - but taper and STOPPED asap.
🔔This contrasts with ACR2021 rec to avoid GC
▶️JAKi no longer equal to bDMARDs, consider usage with risk assessment
@RheumNow https://t.co/fotMgdrFop
Eric Dein ericdeinmd ( View Tweet)
What is the wait period for a patient to see a rheumatologist in your country?
Danish laws mandates the wait for a rheumatologist cannot be longer than 4 weeks (either by telemedicine or in person appts). #EULAR2022 @rheumnow https://t.co/TaYysIyGSi
TheDaoIndex KDAO2011 ( View Tweet)
“Tomorrow’s challenge is not to accumulate data, it’s to store, platform, analyse and make the most of these data. It will need to be #digital and #human” @DanielAletaha during the #EULAR2022 opening ceremony @RheumNow
Aurelie Najm AurelieRheumo ( View Tweet)
Does AI really help to diagnose RMDs? Well this is the question we will try to answer today. We are waiting for you in Hall D5 for the AI session starting at 2.15pm ✨
@DiegoBenavent @eular_org #EULAR2022
@RheumNow https://t.co/JoKELQKMcE
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2022 ANCA associated recommendations:
Bactrim prophylaxis recommended for patients on RTX, CYC, and/or high dose glucocorticoids 💊
@RheumNow https://t.co/5JvcZpI5jq
Eric Dein ericdeinmd ( View Tweet)
#EULAR2022 AAV Reccs Revised: Plasma exchange can be considered for pts with GPA/MPA in pts w/active GN (not for alveolar hemorrhage) @rheumnow https://t.co/zkJljHgly4
TheDaoIndex KDAO2011 ( View Tweet)
Where is overall mattock disease following a covid vaccine range from 4.4 to 14.9% period this study of 4627 showed an 11.7% flare rate within 3 months of VAX #EULAR2022 abtr POS 0200 https://t.co/sxI4791rll
Dr. John Cush RheumNow ( View Tweet)
Baricitinib fails in 2 phase 3 lupus trials, BRAVE I & II #EULAR2022 abtr POS 0190 https://t.co/ecGA2A42kP
Dr. John Cush RheumNow ( View Tweet)
Voclosporin in lupus nephritis - good 3 year continuation data. #EULAR2022 abtr POS 0186 https://t.co/s4Dj6ZTh71
Dr. John Cush RheumNow ( View Tweet)
Bridge Prednisone Use Fails to Improve Outcomes
A one year, X-ray outcome trial has shown that the initial use of prednisone (high or low dose) in newly treated active early rheumatoid arthritis (RA) did not improve radiographic outcomes.
https://t.co/Ugl05Mljwj https://t.co/zXYYTHE7yW
Links:
Dr. John Cush RheumNow ( View Tweet)
Tuesday Night Rheumatology: HOT TOPICS IN RHEUMATOLOGY https://t.co/tMMrRU3sXa
Dr. John Cush RheumNow ( View Tweet)